Everything that's happened at Trump Generic Drug Tariffs

Dr Reddy's CEO GV Prasad said shifting generic drug manufacturing to the US is not practical under Trump's tariff plan.

Prasad stated the company will not take special action due to the announcement but will learn and evolve accordingly.

The CEO emphasized the impracticality of moving manufacturing given existing cost structures and supply chains.

President Trump's policy phases in tariffs on generic drugs starting at 0% for two years, reaching 200% after 2028.

The tariff schedule begins August 1, 2026, with incremental increases to incentivize domestic production.

The policy aims to boost US manufacturing of generic medicines, reducing reliance on imports.

The announcement impacts global pharmaceutical supply chains, particularly affecting Indian generic drug exporters.

US President Donald Trump announced phased tariffs on imported generic medicines, starting with zero tariffs from August 1, 2026, for two years.

Tariffs will rise to 100% from August 2028 and 200% from August 2029, aiming to encourage manufacturing in the United States.

Indian drugmakers export approximately $9-10 billion worth of generic medicines to the US annually, accounting for nearly 40% of generic medicines used in the US.

India's pharmaceutical exports to the US stood at $10.5 billion in 2024-25, making medicines a top export category.

The tariff plan targets reshoring generic pharmaceutical production to America, potentially impacting India's role as the 'pharmacy of the world'.